Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J buying Scios for $2.69bn cash

Executive Summary

Johnson & Johnson has agreed to acquire Scios Inc. (public biotech; cardiovascular and autoimmune therapeutics) for $2.69bn (or $2.4bn, net of Scios's cash). Scios stockowners will receive $45 for each common share they hold, a 35% premium to the market average in the period before the negotiations were first rumored.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register